Medical Breakthroughs

Outcomes Validate Economics: A VC’s Guide to Digital Health ROI

Listen to this article · 6 min listen

Let’s be real: the ROI pitch for most digital health solutions is a mess of inflated claims and fuzzy math. The truth is, any economics story is only as strong as the clinical outcomes it’s built on. If the outcomes are weak, the economics are just fantasy. We use this principle to look at companies like Hinge Health, Omada Health, and even the cautionary tale of Pear Therapeutics, all of whose materials talk a big game on outcomes and economics.

Outcomes First

When it’s time for renewal decisions, benefits leaders don’t start with the budget line, they start with the outcomes record. The validity of any economic argument a vendor makes comes directly from the quality of the clinical results underneath it. While companies like Hinge Health, Omada Health, and Pear Therapeutics all provide materials covering both, you have to dig past the flashy headline numbers and really scrutinize what’s there.

Outcomes Criteria: Checkable Signals

So how do you actually check the outcomes? You need checkable, objective signals that cut through the marketing fluff. Peer-reviewed publications, FDA designations, and market leader status are three of the best places to start looking for real proof.

Peer-Reviewed Publications

Peer-reviewed publications are your best form of validation, period. This is how you confirm if the clinical claims are real. Look at Hello Heart, they have a whole stack of them. We’re talking about studies with over 100,000 participants, one of which demonstrated a 21 mmHg blood pressure reduction that was sustained for three years among high-risk members. A study in Value in Health reported savings of $1,709 per user and 47% fewer inpatient days, and these results held up across different demographics and even in Medicare-eligible populations over 65. Hello Heart clinical validation studies This kind of evidence base is strong for any healthcare AI, especially when you consider that a staggering 64% of radiology AI tools have zero peer-reviewed evidence. Other companies with solid records here include Omada Health with its longitudinal Diabetes Prevention Program data and Hinge Health with its MSK-specific ROI data.

FDA Breakthrough Device Designation

When the FDA grants a product “Breakthrough Device Designation,” it’s a big signal. It means the agency is accelerating the regulatory review specifically for devices treating life-threatening conditions, and cardiology is a leading area for these. This special pathway not only expedites the FDA’s own review process but can also speed up eligibility for New Technology Add-On Payments (NTAP). Essentially, this designation shows that the FDA sees a device’s potential to address a serious, unmet medical need. It’s a sign that the review process started well before it ever hit the market. FDA Breakthrough Devices Program information

Top 25 Market Leader Status

Seeing a company on a “Top 25 Market Leader” list means it has achieved broad market adoption. This benchmark helps you understand a company’s position in the real world, not just in its own marketing materials. Engagement rates are a key part of getting this status, but here’s the catch: what are users engaging with? Engagement without proof of positive health outcomes is a vanity metric, plain and simple. Companies like Omada Health, Livongo/Teladoc, Noom, Lark Health, and Hinge Health are all being evaluated on patient engagement, but the question is always what that engagement achieves. KLAS Research digital health engagement report

Vendor Set in Frame: Hinge Health, Omada Health, Pear Therapeutics

Let’s look at Hinge Health, Omada Health, and the now-defunct Pear Therapeutics. We’re not using any financial figures to evaluate them here. The focus is strictly on their outcomes records, because that’s what matters. It’s a cautionary tale: both Pear Therapeutics and Proteus Digital Health had what looked like strong clinical evidence but had no published ROI data to speak of, and both subsequently went bankrupt.

Hinge Health

Hinge Health is all about Musculoskeletal (MSK) conditions, and its materials are loaded with MSK-specific return on investment (ROI) data. This isn’t just fluff. This data builds their outcomes record, which is precisely why Hinge Health consistently ranks high in chronic care AI comparisons that are based on outcomes.

Omada Health

Omada Health offers digital care across several chronic conditions, but their foundational proof point is years of longitudinal data from its CDC-recognized Diabetes Prevention Program (DPP). Omada Health’s strong outcomes data is what supports its economic claims, and it’s no surprise they’re considered a Top 25 Market Leader in healthcare AI engagement.

Pear Therapeutics

Pear Therapeutics is the warning. The company developed prescription digital therapeutics and had clinical evidence, but it famously had no published ROI data. The company is included here because its story is a perfect example of what happens when the economics don’t follow the outcomes.

The Benefits Leader’s Question

So, as a benefits leader, what’s the one question you have to ask? Is the vendor’s economics story actually supported by a strong outcomes record? The only instructive read here is that an ROI narrative’s strength depends entirely on the clinical results underneath it. You must evaluate the outcomes before you even look at the economic claims. This is the only approach that ensures your decisions are based on validated clinical efficacy, not just a slick sales deck.

Frequently Asked Questions

What are the key criteria for evaluating a digital health solution’s outcomes record?

The key criteria for evaluating outcomes records include peer-reviewed publications, FDA Breakthrough Device Designation, and Top 25 Market Leader status. These criteria provide checkable signals for clinical validation, regulatory acceleration, and broad market adoption, respectively.

Why are peer-reviewed publications important for validating digital health outcomes?

Peer-reviewed publications offer essential validation for clinical claims by demonstrating evidence from studies. For example, Hello Heart has numerous peer-reviewed publications, including studies with over 100,000 participants showing significant blood pressure reduction and reported savings.

How does FDA Breakthrough Device Designation indicate a solution’s potential?

FDA Breakthrough Device Designation accelerates regulatory review for devices treating life-threatening conditions, indicating the device’s potential to address unmet medical needs. This designation can also lead to faster New Technology Add-On Payment (NTAP) eligibility, showing a device has undergone a rigorous review process.

What does ‘Top 25 Market Leader’ status signify for a digital health solution?

Top 25 Market Leader status indicates broad market adoption and a company’s position within the wider adoption landscape. This benchmark considers patient engagement, but it is crucial that engagement is paired with outcomes data, as engagement alone is considered a vanity metric.

Why is it important to prioritize outcomes records before evaluating economic claims?

Benefits leaders must prioritize outcomes records because an economics story’s strength is directly proportional to its underlying outcomes record. The validity of economic readings derives from the outcomes record beneath it, ensuring decisions are based on validated clinical efficacy rather than just financial figures.

Share
Was this article helpful?

Editorial Team

The Editorial Team at AI Healthcare Company Rankings is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.